In my jet lagged stupor (HI! I’m back!) I reached for my phone in the middle of the night, and as I scrolled through my social media feeds, I was promptly alerted to the fact that Animas Corporation, a Johnson & Johnson Diabetes Care company, was out of business. Effective immediately, Animas pumps would no longer be supplied in the US or Canada
My initial thought: ‘No surprises here.’
My second thought: ‘What a mess.’
(My third thought: ‘Jet lag sucks.’)
So, what does this mean for Australia? Australian Medical and Scientific Limited (AMSL), the Australian distributors of the Animas pump, have today stated that the overnight announcement does not affect Australia. Supply of Animas pumps, pump consumables and technical support will continue.
So, business as usual?
Well yes. It is. And that’s great for people who are using Animas here in Australia. Unlike our friends in the US, we are not suddenly being forced to make an urgent decision about which pump will be changing to.
But can we say business as usual when we know not that there will be no upgraded, updated or new technology from Animas in the future? I don’t really think so. One of the important factors of diabetes tech is the element of ‘what’s next?’ There is no ‘what’s next?’ from this company.
The pump market seems to keep getting smaller. Deltec Cozmo and now Animas are all out of the game in Australia leaving us with less and less choice. (Cellnovo has delayed their 1 October launch for another month.)
My fear is that we will end up with no choice at all. I am very much turned to the US right now with my eyes are firmly planted on Bigfoot Biomedical and Beta Bionics as I watch the developments of their automated delivery device systems. And, of course, I have particular interest in how they are going to supply markets outside the US. Are they even going to supply markets like Australia?
This is not a good day for people with diabetes.

Happier days with my Animas Vibe pump.
7 comments
Comments feed for this article
October 6, 2017 at 4:30 pm
bec3116
I don’t understand how this critical part of the diabetes consumer market is shrinking? It is a growing consumer market isn’t it? Is the cost of keeping up with consumer demands and medical science just too great for these companies? Do they not care that the quality of life of people living with type 1 diabetes is significantly diminished without the opportunity to buy in on (at significant costs mind you) he advancements they have been promising for so long? What is worse is this shamefully disappointing decision is actually not at all surprising to me.
LikeLike
October 11, 2017 at 12:49 pm
RenzaS / Diabetogenic
I don’t know the answers to any of those questions, Bec, but I do share your frustrations and sadness about it. I despair that we are heading to not having any choice about which device we have to use, and that terrifies me…
LikeLike
October 6, 2017 at 7:25 pm
Jeann
Bummer! I agree with bec in that I thought diabetes was a growing market.
LikeLiked by 1 person
October 6, 2017 at 10:37 pm
Ann Morris
It is not good that competition has diminished in the pump market place. I know we are a small market but we still need pump companies to see us as a viable market – one worth fighting for.
No competition is not good for anyone w Diabetes wanting pump therapy.
LikeLiked by 1 person
October 11, 2017 at 12:49 pm
RenzaS / Diabetogenic
I agree, Ann.
LikeLike
October 7, 2017 at 11:27 am
StephenS
Like you, I fear that choice was slowly, and is now quickly, being profit-margined out of the market. I’m not panicking yet, but I don’t like being forced into something not of my own choosing.
LikeLiked by 1 person
October 11, 2017 at 12:50 pm
RenzaS / Diabetogenic
It’s not a great situation, is it, Stephen? I really hate feeling like my health condition is being ‘profit-margined’. It’s just another reason to feel resentful about having diabetes.
LikeLike